Recent Updates
Recently added Catalysts
MNKD Positive Sentiment

MannKind to Present at Upcoming Investor Conferences

Key Takeaway: MannKind Corporation has announced its participation in two upcoming investor conferences. The management team will present at the Cantor Global Healthcare Conference on September 10, 2026, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live audio webcasts will be available on their website, along with recorded versions post-conference.
Price reaction · baseline $3.98 (2026-09-01 close) · hit pre-market · clean, no other MNKD news in the window
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • MannKind is actively engaging with investors.
  • The company is presenting at multiple notable conferences.
  • They focus on innovative solutions for chronic diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.1%
average across 14 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Fursemide for administration
Phase 2 · Heart Failure

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences:

Cantor Global Healthcare Conference (New York, NY) Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY) Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET

Links to the live audio webcasts of the presentations will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available on the website for approximately 90 days following the conference.
About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.

Frequently Asked Questions

When will MannKind present at the Cantor Conference?

MannKind will present at the Cantor Global Healthcare Conference on September 10, 2026.

Where can I find the webcasts of the presentations?

The live audio webcasts will be available on MannKind's website.

What is MannKind's focus in biopharmaceuticals?

MannKind focuses on cardiometabolic and orphan lung diseases.

How long will the recorded presentations be available?

Recorded versions will be available for approximately 90 days after the conferences.

Last updated: Sep 2, 2026